• Absolutely avoid foods high in sodium. As an experiment, I have found I can bring on a "cramp attack" within 20 minutes by eating a handful of salty pretzels. Keep in mind all prepared foods, such as canned soups and frozen dinners, are very high in sodium.
• Eat a high-choline food item three times a week (refer to the thread "Foods high in choline" on this forum for details).
• Gently exercise the affected area (for me, the legs) three times per week.
• Gently stretch the affected area daily before bed.

quote:

Meanwhile, topline results from the phase III TACTT2 trial of Auris Medical’s (NASDAQ:EARS) tinnitus candidate AM-101 are expected in August. A European trial is also due to report before the end of the year. These could put it on track to become the first drug approved for the acute form of the disease, though earlier clinical data were mixed.

The co-primary endpoints in Auris's phase III TACTT2 trial are change in tinnitus loudness and the tinnitus functional index score, which measures tinnitus impact and burden, from baseline to day 84.

AM-101, also known as Keyzilen, is an NMDA receptor antagonist designed to suppress aberrant excitation of the auditory nerve that is thought to underlie the development of tinnitus.

There are no treatments approved for the disorder, but commonly used agents include oral corticosteroids, ginkgo biloba and benzodiazepines, as is masking by another stimulus. 84% of US ear, nose and throat physicians are dissatisfied with these, according to LifeSci Capital analysts.

If AM-101 succeeds it will hit a market ripe for disruption. But the signals so far have been mixed: a phase II trial failed to show a treatment benefit on its primary endpoint of minimal masking level – the lowest level at which the tinnitus can be masked by a stimulus – although it did hit other endpoints including tinnitus loudness (Upcoming events: MEI’s HDAC inhibitor data and futility from Auris in tinnitus, March 6, 2015).

AM-101 is also in a European trial, TACTT3, expected to report results in the fourth quarter. This has a similar design to TACTT2, but includes a second cohort evaluating patients with post-acute tinnitus between three and 12 months from onset.

Auris will likely wait until the TACTT3 data are available before filing the project with the FDA, Leerink analysts believe. They give it a 60% chance of success and put peak risk-adjusted sales at $350m.

LifeSci Capital analysts are more optimistic, saying the potential US market size for AM-101 is up to $630m. The acute form of the disease affects around 500,000 people in the US. The analysts note that the volume of patients could increase if an effective treatment becomes available.